イシハラ　ヒロキ   Ishihara Hiroki   石原　弘喜    所属   医学部 医学科（東京女子医科大学病院）    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
掲載誌名	正式名：Medical oncology (Northwood, London, England) 略　 称：Med Oncol ISSNコード：1559131X/13570560
掲載区分	国外
巻・号・頁	36(4),pp.35
著者・共著者	Ishihara Hiroki, Takagi Toshio, Kondo Tsunenori, Tachibana Hidekazu, Fukuda Hironori, Yoshida Kazuhiko, Iizuka Junpei, Kobayashi Hirohito, Okumi Masayoshi, Ishida Hideki, Tanabe Kazunari
担当区分	筆頭著者,責任著者
発行年月	2019/03
概要	The correlation between the magnitudes of best tumor response (bTR) and patient survival in immune checkpoint inhibitor therapy for metastatic renal cell carcinoma (mRCC) remains unclear. In this article, we retrospectively investigated the prognostic association of the magnitude of bTR in nivolumab therapy for mRCC. Fifty-five patients treated with nivolumab after failure of at least one molecular-targeted therapy were evaluated. Assessment of the magnitude of bTR was based on the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. Endpoints were progression-free survival (PFS) and overall survival (OS) after the initiation of nivolumab therapy. In regard to the magnitude of bTR, complete response, partial response, stable disease, and progressive disease were observed in three (5.46%), 15 (27.3%), 19 (34.5%), and 18 (32.7%) patients, respectively. PFS and OS were significantly correlated with the magnitude of bTR (median PFS: not reached (N.R.) [95% confidence interval (CI) 16.8-N.R.] vs. 13.0 [8.38-56.0] vs. 5.95 [4.27-7.30] vs. 1.92 [0.53-3.91] months, p < 0.0001; OS: N.R. [N.R.-N.R.] vs. N.R. [21.4-N.R.] vs. 23.3 [23.3-N.R.] vs. 7.36 [1.41-N.R.] months, p < 0.0001). In addition, multivariate analyses show that the magnitude of bTR was an independent factor for PFS (p < 0.0001) and OS (p = 0.0010). In conclusion, this retrospective study shows the significant correlation between the magnitude of bTR and patient survival in nivolumab therapy for mRCC. The magnitude of bTR can be an effective surrogate marker for survival.
DOI	10.1007/s12032-019-1261-5
PMID	30879157